Cargando…

Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro

BACKGROUND: Anti-CD19 chimeric antigen receptor T cells (CART-19) frequently induce remissions in hemato-oncological patients with recurred and/or refractory B-cell tumors. However, malignant cells sometimes escape the immunotherapeutic targeting by CD19 gene mutations, alternative splicing or linea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ledererova, Aneta, Dostalova, Lenka, Kozlova, Veronika, Peschelova, Helena, Ladungova, Adriana, Culen, Martin, Loja, Tomas, Verner, Jan, Pospisilova, Sarka, Smida, Michal, Mancikova, Veronika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378389/ https://www.ncbi.nlm.nih.gov/pubmed/34413165 http://dx.doi.org/10.1136/jitc-2021-002352

Ejemplares similares

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
por: Mancikova, Veronika, et al.
Publicado: (2020)

CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
por: Kozlova, Veronika, et al.
Publicado: (2020)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
por: Mancikova, Veronika, et al.
Publicado: (2021)

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL
por: Diorio, Caroline, et al.
Publicado: (2022)

TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
por: Shaw, Lauren C., et al.
Publicado: (2022)

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
por: Lu, Chunwan, et al.
Publicado: (2020)

Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients
por: Parvathaneni, Kalpana, et al.
Publicado: (2021)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

CD34(+)CD19(−)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
por: Bueno, Clara, et al.
Publicado: (2022)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

Loss of an Immunodominant HLA-Α *01:01 Restricted Epitope for CD8+ Cytotoxic T Lymphocytes (CTLs) in the Delta Variant of COVID-19: An Example of Immunologic Escape and Implications for Immunologic Treatment
por: Flomenberg, Neal, et al.
Publicado: (2021)

Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage
por: Mancikova, Veronika, et al.
Publicado: (2022)

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
por: Lu, Chunwan, et al.
Publicado: (2021)

COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Rogiers, Aljosja, et al.
Publicado: (2021)

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
por: Rouhani, Sherin Juliet, et al.
Publicado: (2022)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
por: Ottaviano, Margaret, et al.
Publicado: (2020)

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
por: Meetze, Kristan, et al.
Publicado: (2023)

Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey
por: Ghosh, Nilasha, et al.
Publicado: (2020)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

MAL promoter hypermethylation as a novel prognostic marker in gastric cancer
por: Buffart, T E, et al.
Publicado: (2008)

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Ruiz, Juan Ignacio, et al.
Publicado: (2023)

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
por: Palomba, M Lia, et al.
Publicado: (2022)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis
por: Ma, Yifei, et al.
Publicado: (2021)

A Case of Suppurative Pleuritis with Gangrene of a Portion of Lung Tissue and Its Escape from the Operation Wound
por: Wagner, W., et al.
Publicado: (1881)

Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells
por: Dave, Zankruti, et al.
Publicado: (2022)

Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
por: Olivo Pimentel, Veronica, et al.
Publicado: (2021)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19
por: Bao, Riyue, et al.
Publicado: (2020)

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)

Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application
por: Hynst, Jakub, et al.
Publicado: (2021)

CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment
por: Christodoulou, Ilias, et al.
Publicado: (2021)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

Escape from planned obsolescence: Hepatitis C, the cirrhotic liver, and clonal expansions
por: Branch, Andrea D.
Publicado: (2020)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3kod7vonepd8okpi46aqiaqqup